A009

Hanall Biopharma Co., Ltd. Stock Price

KOSE:A009420 Community·₩1.8t Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A009420 Share Price Performance

₩34,950.00
-8400.00 (-19.38%)
₩34,950.00
-8400.00 (-19.38%)
Price ₩34,950.00

A009420 Community Narratives

There are no narratives available yet.

Recent A009420 News & Updates

Subdued Growth No Barrier To Hanall Biopharma Co., Ltd.'s (KRX:009420) Price

Aug 11
Subdued Growth No Barrier To Hanall Biopharma Co., Ltd.'s (KRX:009420) Price

We're Hopeful That Hanall Biopharma (KRX:009420) Will Use Its Cash Wisely

Jun 11
We're Hopeful That Hanall Biopharma (KRX:009420) Will Use Its Cash Wisely

Hanall Biopharma Co., Ltd. (KRX:009420) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Mar 20
Hanall Biopharma Co., Ltd. (KRX:009420) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Is Hanall Biopharma Co., Ltd. (KRX:009420) Trading At A 22% Discount?

Feb 25
Is Hanall Biopharma Co., Ltd. (KRX:009420) Trading At A 22% Discount?

Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Dec 09
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Hanall Biopharma Co., Ltd. Key Details

₩150.1b

Revenue

₩70.2b

Cost of Revenue

₩79.9b

Gross Profit

₩77.6b

Other Expenses

₩2.2b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
44.00
Gross Margin
53.21%
Net Profit Margin
1.49%
Debt/Equity Ratio
0%

Hanall Biopharma Co., Ltd. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
4 Rewards

About A009420

Founded
1973
Employees
304
CEO
Sean Jeong
WebsiteView website
www.hanall.co.kr

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson’s disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves’ disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

South Korean Market Performance

  • 7 Days: 1.6%
  • 3 Months: 13.5%
  • 1 Year: 35.3%
  • Year to Date: 47.0%
Over the last 7 days, the market has risen 1.6%, driven by gains of 6.0% in the Information Technology sector. As for the past 12 months, the market is up 35%. Earnings are forecast to grow by 24% annually. Market details ›